中期報告 截至二零二五年六月三十日止六個月 INTERIM REPORT 2025 中 期 報 告 公司主要財務指標 本公司自二零二零年二月二十四日開始按照中國企業會計準則編製境外財務報表，本公司截至二零二五年六月三十 日止六個月（「報告期」）的主要財務數據如下： 一、公司主要會計數據和財務指標 （一）五年財務摘要 業績 | | | | 未經審核 | | | | --- | --- | --- | --- | --- | --- | | | | | 截至六月三十日止六個月 | | | | | 二零二五年 | 二零二四年 | 二零二三年 | 二零二二年 | 二零二一年 | | | 人民幣千元 | 人民幣千元 | 人民幣千元 | 人民幣千元 | 人民幣千元 | | 收入 | 390,083 | 408,124 | 522,828 | 271,260 | 399,037 | | 除所得稅前利潤╱（虧損） | 5,622 | 72,187 | 63,433 | (61,189) | 66,787 | | 所得稅費用 | – | (1,843) | 5,172 | 25,169 | (1,717) | | 本期利潤╱（ ...

Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 785.25%, Hongye Futures (03678) at 250.59%, and Andeli Juice (02218) at 244.32% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -18.40%, Hengrui Medicine (01276) at 3.92%, and China Merchants Bank (03968) at 7.34% [1] - The article provides a detailed ranking of the top ten and bottom ten AH stocks based on their premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The top three companies with the highest deviation values are Jinli Permanent Magnet (06680) at 37.37%, Andeli Juice (02218) at 33.98%, and Fudan Zhangjiang (01349) at 22.87% [1] - Conversely, the bottom three companies with the lowest deviation values are BYD Company (01211) at -75.67%, Longpan Technology (02465) at -57.24%, and Changfei Optical Fiber Cable (06869) at -31.37% [1][2] - The article emphasizes the importance of monitoring these premium rates and deviation values as indicators of potential investment opportunities and market inefficiencies [1][2]

格隆汇8月27日丨复旦张江(688505.SH)公布，公司于近日收到王海波先生发来的《关于减持复旦张江股 份计划的告知函》，因自身资金需求，王海波先生计划自本公告披露之日起15个交易日后的3个月内通 过集中竞价的方式减持公司股份不超过10万股，拟减持比例不超过公司总股本的0.01%。 ...

证券代码：688505 证券简称：复旦张江 公告编号：临 2025-028 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，上海复旦张江生物医药股份有限公司（以下简称"公司" 或"复旦张江"）股东王海波先生持有公司股份 51,828,605 股，占公司总股本的 5.00%。王海波先生所持有的公司股份来源为公司首次公开发行前取得的股份， 该部分股份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 减持计划的主要内容 公司于近日收到王海波先生发来的《关于减持复旦张江股份计划的告知函》， 因自身资金需求，王海波先生计划自本公告披露之日起 15 个交易日后的 3 个月 内通过集中竞价的方式减持公司股份不超过 100,000 股，拟减持比例不超过公司 总股本的 0.01%。 根据王海波先生于《复旦张江首次公开发行股票并在科创板上市招股说明书》 作出的承诺："本人减持所持有公司股份 ...

Core Viewpoint - Fudan Zhangjiang Biopharmaceutical Co., Ltd. announced that shareholder Wang Haibo holds 51.8286 million shares, representing 5.00% of the total share capital, and plans to reduce his holdings due to personal funding needs [1] Group 1 - Wang Haibo's shares were acquired before the company's initial public offering and have been fully released from restrictions since June 19, 2023 [1] - Wang Haibo intends to reduce his holdings by no more than 100,000 shares within three months, which would account for up to 0.01% of the company's total share capital [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於持股 5%以上股東減持股份計劃公告》，僅供參閱。該文件及其披露內容乃根據中國 法律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 趙大君先生（執行董事） 中國·上海 二零二五年八月二十七日 *僅供識別 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-028 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本 ...

Core Insights - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 770.97%, Hongye Futures (03678) at 252.57%, and Andeli Juice (02218) at 238.08% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -18.73%, Midea Group (00300) at 6.86%, and Heng Rui Medicine (01276) at 7.43% [1][2] - The companies with the highest deviation values are Beijing Machinery (00187) at 32.43%, Andeli Juice (02218) at 29.55%, and Fudan Zhangjiang (01349) at 29.44% [1][3] - The companies with the lowest deviation values are BYD (01211) at -84.97%, Longpan Technology (02465) at -62.46%, and GAC Group (02238) at -26.17% [1][3] AH Premium Rate Rankings - The top AH stocks by premium rate include: - Northeast Electric (00042): H-share at 0.310 HKD, A-share at 2.25 CNY, premium rate 770.97%, deviation -23.02% [2] - Hongye Futures (03678): H-share at 4.280 HKD, A-share at 12.6 CNY, premium rate 252.57%, deviation 25.11% [2] - Andeli Juice (02218): H-share at 17.780 HKD, A-share at 50.18 CNY, premium rate 238.08%, deviation 29.55% [2] - The bottom AH stocks by premium rate include: - CATL (03750): H-share at 410.200 HKD, A-share at 278.3 CNY, premium rate -18.73%, deviation 1.21% [2] - Midea Group (00300): H-share at 81.500 HKD, A-share at 72.71 CNY, premium rate 6.86%, deviation -1.78% [2] - Heng Rui Medicine (01276): H-share at 72.500 HKD, A-share at 65.03 CNY, premium rate 7.43%, deviation 11.64% [2] Deviation Value Rankings - The top AH stocks by deviation value include: - Beijing Machinery (00187): H-share at 4.950 HKD, A-share at 13.24 CNY, premium rate 220.40%, deviation 32.43% [3] - Andeli Juice (02218): H-share at 17.780 HKD, A-share at 50.18 CNY, premium rate 238.08%, deviation 29.55% [3] - Fudan Zhangjiang (01349): H-share at 3.590 HKD, A-share at 10.06 CNY, premium rate 235.65%, deviation 29.44% [3] - The bottom AH stocks by deviation value include: - BYD (01211): H-share at 115.100 HKD, A-share at 110.68 CNY, premium rate 15.18%, deviation -84.97% [3] - Longpan Technology (02465): H-share at 10.320 HKD, A-share at 14.37 CNY, premium rate 66.76%, deviation -62.46% [3] - GAC Group (02238): H-share at 3.690 HKD, A-share at 7.88 CNY, premium rate 155.83%, deviation -26.17% [3]

Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 743.75%, Hongye Futures (03678) at 241.98%, and Andeli Juice (02218) at 236.37% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -16.43%, Heng Rui Medicine (01276) at 1.82%, and Midea Group (00300) at 4.90% [1] - The article provides a detailed table of the top ten and bottom ten AH stocks based on premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The deviation values for the top three companies are Andeli Juice (02218) at 32.29%, Jinli Permanent Magnet (06680) at 22.19%, and Beijing Machinery (00187) at 20.80% [1] - The companies with the lowest deviation values include BYD Company (01211) at -98.36%, Northeast Electric (00042) at -64.84%, and Longpan Technology (02465) at -51.92% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]

前十大AH股偏离值排行 股票名称 H股(港元) A股 溢价率 偏离值↓ 安德利果汁(02218) 18.420 51.94 237.73% 38.61% 京城机电股份 (00187) 5.240 13.73 213.93% 30.46% 钧达股份(02865) 22.460 48.23 157.21% 17.54% 金力永磁(06680) 19.020 29.57 86.23% 16.30% 复旦张江(01349) 3.820 10.16 218.59% 15.27% 凯盛新能(01108) 4.690 11.22 186.57% 13.05% 山东墨龙(00568) 4.400 6.53 77.73% 12.87% 农业银行(01288) 5.530 7.23 56.60% 12.14% 龙源电力(00916) 6.810 16.7 193.69% 12.06% 泰格医药(03347) 51.250 66.7 55.88% 11.18% 后十大AH股偏离值排行 股票名称 H股(港元) A股 溢价率 偏离值↑ 比亚迪股份(01211) 111.400 108.25 16.39% -111.35% 东北电气 ( ...

Group 1 - The Shanghai Composite Index fell by 0.02% to close at 3727.29 points, while the Hang Seng Index decreased by 0.21% to 25122.9 points [1] - Fudan Zhangjiang's A/H premium reached 183.21%, ranking third among A/H shares [1] - At market close, Fudan Zhangjiang's A-shares were priced at 10.48 yuan, down 1.87%, and H-shares were at 4.02 HKD, down 1.95% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new drugs expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and "Major New Drug Creation" projects [1]